Ignite Creation Date:
2024-05-06 @ 8:22 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02722408
Status:
COMPLETED
Last Update Posted:
2020-06-25
First Post:
2016-03-12
Brief Title:
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-Lowering Therapy COBALT-1
Sponsor:
NeuroBo Pharmaceuticals Inc
Organization:
NeuroBo Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Open-Label Dose-Finding Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid Lowering Therapy COBALT-1
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to assess the efficacy safety and tolerability of multiple doses of Gemcabene in patients with HoFH on stable lipid-lowering therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None